1. Home
  2. MEC vs CBIO Comparison

MEC vs CBIO Comparison

Compare MEC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mayville Engineering Company Inc.

MEC

Mayville Engineering Company Inc.

N/A

Current Price

$15.76

Market Cap

527.1M

Sector

Industrials

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.97

Market Cap

488.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MEC
CBIO
Founded
1945
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
527.1M
488.1M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
MEC
CBIO
Price
$15.76
$12.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
★ $37.00
$31.50
AVG Volume (30 Days)
★ 406.4K
287.1K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $18,500.00
Revenue This Year
$16.40
N/A
Revenue Next Year
$14.08
$177.36
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.42
$8.72
52 Week High
$38.76
$27.41

Technical Indicators

Market Signals
Indicator
MEC
CBIO
Relative Strength Index (RSI) 53.56 41.73
Support Level $14.36 $11.78
Resistance Level $18.84 $13.54
Average True Range (ATR) 0.85 0.99
MACD 0.39 0.20
Stochastic Oscillator 86.12 34.81

Price Performance

Historical Comparison
MEC
CBIO

About MEC Mayville Engineering Company Inc.

Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: